Powerful Dialogue | Mu Ziteng and Guo Rui Yinuo Engage in In-Depth Discussions, Kicking Off a New Journey of Business Cooperation
Release time:
2025-11-20 09:28
Keywords:
Negotiation,Investment
On the morning of November 18, 2025, Huazhong Linghua General, leading a team of three members from Mu Ziteng (Shanghai) Enterprise Management Consulting Co., Ltd. (hereinafter referred to as "Mu Ziteng"), visited Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd. (hereinafter referred to as "Guorui Yinuo") for an inspection and exchange. Su Lai, General Manager of Guorui Yinuo, and Yin Qianyu, Head of the Marketing Department of Huaxin Yinuo, warmly welcomed the delegation. The two sides held in-depth discussions on business cooperation and investment opportunities in the field of pharmaceutical safety evaluation, and reached an agreement on cooperation intentions.
Led by Yin Qianyu, head of the Marketing Department at Huaxin Yinuo, the delegation from Huazong visited, in turn, Guorui Yinuo’s biosafety laboratory, animal laboratory, and medical device operating room—among other core laboratories. Yin Qianyu provided a detailed introduction to the company’s preclinical R&D processes for new drugs and medical devices, as well as the hardware configurations, technical standards, and operational status of each laboratory.
The company’s laboratory covers an area of approximately 7,500 square meters and is equipped with cutting-edge, fully automated blood analyzers, anesthesia machines, and other high-end equipment that are internationally leading. It has also established a comprehensive quality-control system compliant with GLP standards, covering multiple fields such as veterinary drug clinical research and medical device development. Moreover, the lab can seamlessly integrate “pre-screening” at the front end with “quality assurance” at the back end, placing high-throughput drug screening ahead of GLP evaluations to create a “one-in-ten-thousand” early-warning mechanism, enabling rigorous, cost-effective, and high-throughput screening. Only those compounds identified as “excellent candidates” will proceed to the formal GLP validation stage. This experimental system, which helps client companies reduce risks, is a unique feature exclusively offered by Guorui Yinuo. Mr. Hua and his delegation highly praised Guorui Yinuo’s meticulous experimental procedures, its comprehensive quality assurance system, and its deep-rooted technological expertise.
At the symposium, Mr. Su from Guorui Yinuo further introduced the company’s business development and core strengths. As the first non-clinical drug research institution in Northwest China to obtain OECD GLP certification, Guorui Yinuo, backed by a core technical team composed of seasoned toxicologists and pharmacologists, has provided high-quality safety evaluation services to several pharmaceutical companies, helping numerous drug candidates advance smoothly into clinical studies. Mr. Su noted that the pharmaceutical industry is currently undergoing accelerated innovation and upgrading, making the professionalism and efficiency of drug safety evaluation critical needs for pharmaceutical companies. Guorui Yinuo has always adhered to the philosophy of “serving our clients,” continuously enhancing its technical service capabilities, and looks forward to collaborating with high-quality partners to expand its market presence.
Representing Muziteng Company, General Manager Hua introduced the company’s business positioning and resource advantages. As a professional firm specializing in corporate management consulting and technology solution provision, the company will fully leverage its strengths to help Guorei Yinuo precisely meet specific needs. General Manager Hua noted that Guorei Yinuo’s technological prowess and market potential in the field of pharmaceutical safety evaluation are truly remarkable, and the two companies are poised to embark on a new journey of collaboration in the future.
This round of talks has established an efficient communication bridge between the two parties. Not only has it enabled Muziteng to gain a more comprehensive understanding of Guorui Yinuo’s business strengths and development prospects, but it has also laid a solid foundation for the two sides to engage in multi-level and multi-sector cooperation in the future. Moving forward, Guorui Yinuo will continue to uphold an attitude of open collaboration, actively connect with high-quality resources, and provide strong support for the safe development of the pharmaceutical industry, working together with its partners to write a new chapter in industrial upgrading.
Related News
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681